Wyss Institute for Biologically Inspired Engineering, Harvard University

Bill provision would allow for alternative test methods in drug development

SCIEX relates that STORMing Cancer researchers are using organ-chips and proteomic analyses to understand how cancer is driven by inflammation


A growing body of evidence suggests that animal models are seriously lacking in both sensitivity and specificity when it comes to predicting drug toxicity in humans.

Quris describes how a new AI approach can improve predictions of which drug candidates will work safely in the human body

New advancements in computer modeling, tissue engineering and other bio-convergence technologies have made the need to test on animals obsolete.

Some studies estimate that as much as 89% of novel drugs entering clinical trials ultimately fail, with as much as 50% of those failing due to toxicities unanticipated by animal models.

New legislation will allow more innovative and human-relevant testing platforms to expedite the development of promising drugs

Sen. John Neely Kennedy (R-La.) plays with dogs belonging to Senate staff members before an Oct. 7 news conference in Washington. (Anna Moneymaker/Getty Images)

This past week, a handful of bipartisan lawmakers introduced two bills aimed at ending one of our nation’s most-barbaric practices — mandatory animal testing of new pharmaceuticals destined for human trials.